Famot

Quick links to important sections

Famot

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Famot

Quick Facts

Property Description
Active ingredient Famotidine
Forms Tablet, Oral Suspension, Solution for Injection
Pharmacological class Histamine H2-receptor antagonist (H2-blocker)
General purpose Managing gastric hypersecretion and acid-related disorders
Origin Synthetic organic compound

What Type of Medicine is Famot?

Famot is a medicinal preparation whose active substance is Famotidine, a synthetic organic compound produced through chemical synthesis. This compound is officially classified as a Histamine H2-receptor antagonist, also known as an H2-blocker. This classification defines the drug's essential nature and positions it among substances that specifically modulate gastric acid production. Famotidine is clinically recognized for its high potency when compared to earlier H2-receptor antagonists, establishing it as a highly effective agent within its class. It is generally supplied as a single-ingredient product, confirming that its pharmacological effects are derived exclusively from this one active substance.


Famotidine's Core Purpose and Function

The core purpose of Famotidine is to function as a powerful antisecretory agent. It achieves this by focusing on the parietal cells in the stomach lining. The drug works by creating a H2 receptor blockade, acting as a competitive antagonist against the natural chemical messenger, histamine. By preventing histamine from binding, the medicine inhibits the cellular mechanism that triggers the significant release of hydrochloric acid. This fundamental effect produces a measurable reduction of gastric acid secretion, which is its core benefit. This targeted action is particularly useful in managing patient discomfort caused by acid-related issues.


Available Forms of Famotidine

Famotidine is formulated in multiple dosage forms, facilitating effective delivery across various needs. The common forms include the solid tablet and the liquid oral suspension for routine use, along with a sterile solution for injection for systemic administration. The primary route of administration is oral, allowing for easy and predictable absorption. The availability of a parenteral form (injection) ensures that the essential benefit of acid suppression can be delivered rapidly and reliably in clinical settings where oral intake is not suitable.

Regulatory References

  1. Famotidine - MedlinePlus

What side effects are possible with Famot?

Possible Side Effects and Safety Information for Famotidine

Adverse Reactions Summary

The most common (ge 1%) adverse reactions reported in clinical trials for famotidine are headache, dizziness, constipation, and diarrhea.

Less frequent adverse effects (uncommon, rare, or very rare) reported from postmarketing surveillance and trials span multiple system-organ classes, including the nervous system (e.g., paresthesia, somnolence, reversible psychic disturbances like confusion and hallucinations), skin (e.g., rash, pruritus, alopecia), and gastrointestinal system (e.g., dry mouth, nausea, vomiting).

Serious adverse reactions are rare and include severe hypersensitivity reactions (e.g., anaphylaxis, angioneurotic edema), severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), severe blood disorders (e.g., agranulocytosis), hepatic events (e.g., cholestatic jaundice), and cardiac rhythm abnormalities (e.g., QT prolongation, AV block).


Safety Considerations and Restrictions

Famotidine is primarily eliminated by the kidneys. Dosage adjustments are required for adult patients with moderate to severe renal impairment (creatinine clearance < 60 mL/min) due to the risk of drug accumulation. Increased systemic exposure in these patients and the elderly is associated with a higher risk of Central Nervous System ( CNS) adverse reactions (confusion, delirium, seizures, lethargy).

The drug is contraindicated in patients with a history of serious hypersensitivity to famotidine or other H2 receptor antagonists. Additionally, a symptomatic response to treatment does not preclude the presence of a gastric malignancy; evaluation for malignancy should be considered in non-responsive patients or those with an early relapse.

Overdose and Emergency Response

The official regulatory profile for Famotidine overdose is defined by specific clinical manifestations and mandated emergency actions. Documented overdose presentations include symptoms such as headache, dizziness, and constipation. More severe systemic overexposure may result in Central Nervous System (CNS) reactions, which are officially documented to include confusion, delirium, agitation, hallucinations, and seizures. Life-threatening outcomes that have been associated with overdose can involve a compromised respiratory status, abnormal heart rhythm, or collapse.

When to Seek Immediate Help

Immediate medical help is required in all cases of suspected overexposure. Regulatory guidance mandates contacting a Poison Control Center or seeking medical attention right away. Critically, if an individual exhibits a seizure, collapses, has trouble breathing, or cannot be awakened, the official requirement is to call emergency services immediately.

Population-Specific Overdose Considerations

The overdose profile specifically identifies groups at increased risk of severe adverse reactions. Official prescribing information states that both elderly patients and individuals with renal impairment face a heightened risk of serious CNS symptoms, such as confusion or delirium. This increased susceptibility is due to the slower elimination of the drug from the body, leading to higher systemic blood concentrations. Management in a healthcare setting is generally classified as symptomatic and supportive treatment.

Therapeutic Uses of Famot

Quick Facts: Famot

  • Relieves symptoms associated with gastroesophageal reflux disease (GERD).
  • Assists in the treatment of active duodenal and gastric ulcers.
  • May help manage pathological hypersecretory conditions.
  • Used for the reduction of the risk of duodenal ulcer recurrence.

Famot is a therapeutic option used to address medical conditions linked to elevated stomach acid production. The medication may help provide relief from the symptoms of gastroesophageal reflux disease (GERD), which occurs when stomach acid flows back into the esophagus. For the management of peptic ulcer disease, Famot assists in the treatment of active ulcers found in the duodenum or the stomach.

In addition to treating active ulceration, the medication is also indicated to reduce the risk of a duodenal ulcer returning after initial healing. Famot is also used to manage conditions in adults that are characterized by the pathological overproduction of stomach acid, such as Zollinger-Ellison syndrome and certain other hypersecretory states. The overall goal of therapy is to stabilize the gastrointestinal environment and support symptomatic relief.

Regulatory References

  1. NIH MedlinePlus guidance on Famotidine

Eligibility and Restrictions for Use

Who Can and Cannot Use Famot?

This section defines the officially documented population eligibility and restrictions for using Famotidine (Famot), based strictly on government regulatory labeling.

Contraindicated Populations

Use of Famotidine is contraindicated (absolutely prohibited) for patients with a known history of serious hypersensitivity reactions to the active ingredient, famotidine, or to any other H2-receptor antagonist ( H2-blocker) due to the risk of cross-sensitivity. Additionally, the injection formulation is not approved in neonates if it contains benzyl alcohol.

Age and Comorbidity Restrictions ️

The medicine is approved for adults and for specific uses in infants (starting at birth for GERD) and children (up to age 17). However, safety and effectiveness are not established for certain pediatric indications, such as the treatment of pathological hypersecretory conditions. Adults with moderate or severe renal impairment (kidney disease) are required to use the medicine under restricted conditions that mandate dosage adjustment. Prior to using Famotidine for a gastric ulcer, regulatory guidance requires that the presence of gastric malignancy must be excluded.

Pregnancy and Lactation

Famotidine is generally not recommended during pregnancy due to a lack of established safety data. For nursing mothers, the drug is excreted in human milk, and official labeling advises that the mother should either stop the drug or stop breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Famotidine (Famot) centers on pharmacokinetic interactions that alter drug concentrations in the body.

Gastric pH Dependent Interactions

Famotidine's acid-reducing effect is the basis for its most common interaction pattern. Co-administration with medicines that require a low gastric pH for adequate absorption—such as certain antivirals, antifungals, and tyrosine kinase inhibitors (e.g., Erlotinib)—can significantly reduce the systemic exposure of the co-administered drug, potentially leading to a loss of efficacy.

Metabolism and Transporter Interactions

The label notes a specific interaction with Tizanidine, where concomitant use may lead to substantially increased Tizanidine blood concentrations due to the inhibition of the CYP1A2 enzyme pathway; avoidance of co-administration is advised where possible. For renal elimination, the co-administration of Probenecid is documented to increase Famotidine's own plasma concentrations by inhibiting its tubular secretion, and co-administration should be avoided.

Administration Requirements

Specific timing rules are noted for agents that interfere with Famotidine's absorption. Antacids and Sucralfate must be separated from Famotidine administration by 1 to 2 hours to ensure Famotidine's proper absorption. Additionally, the label identifies renal impairment as a population-specific constraint, as reduced kidney function results in higher Famotidine blood levels, increasing the risk for exposure-related adverse effects.

Mechanism of Action

Famotidine functions as a highly selective competitive antagonist for the histamine H2 receptor ( H2 R). This receptor is primarily expressed on the parietal cells located within the gastric mucosa of the stomach wall.

By binding reversibly to the H2 R, Famotidine prevents the binding of histamine, an endogenous signaling molecule released by enterochromaffin-like (ECL) cells. This receptor interaction type is critical because histamine normally activates an intracellular signaling cascade involving adenylyl cyclase and the subsequent production of cyclic AMP (cAMP). Increased cAMP levels ultimately lead to the stimulation and insertion of the H^+ / K^+ -ATPase (proton pump) into the cell's apical membrane. Famotidine's action causes a profound pathway modulation by reducing the intracellular cascade that drives the activity of this pump. The final system-level physiological consequence is a decrease in both the volume and the hydrogen ion concentration (acidity) of gastric secretions produced by the stomach.

Dosage and Administration Information

How Famotidine is Used

The administration of Famotidine is governed by prescribing information, which details the appropriate dosage form, route, and schedule for use. The medicine is primarily taken via the oral route as tablets or oral suspension for general use. The intravenous (IV) route is reserved for short-term use in hospitalized patients who are temporarily unable to take the oral formulation.


Dosing and Frequency Patterns

Standard adult regimens typically follow schedules of either 20 mg twice daily or 40 mg once daily at bedtime. The specific frequency and duration are determined by the condition being addressed. For instance, treatment for active ulcers is generally a short course, often up to eight weeks, while maintenance therapy to prevent ulcer recurrence may extend for up to one year.


Administration Conditions and Adjustments

Famotidine tablets and suspension may be taken with or without food. For the IV solution, administration must be performed slowly, either as an injection over at least two minutes or diluted for an infusion over 15 to 30 minutes. A critical principle of use involves dose modification for patients with renal impairment. When creatinine clearance is below 50 mL/min, the daily dose is typically reduced by 50% or the dosing interval is extended to 36 or 48 hours to prevent drug accumulation.

Recent Clinical Evidence

Research evidence / Overview of studies for Famot (Famotidine)

The clinical research base for Famotidine is documented primarily through controlled studies, including Randomized Controlled Trials (RCTs), comparative trials, and maintenance trials, focusing on conditions related to gastric acid secretion. This overview describes what the research has explored and what the existing findings indicate, without offering any clinical advice.


Evidence for Healing and Preventing Peptic Ulcers

Research examined studies in the context of active ulcers found in the stomach (gastric) and the upper small intestine (duodenum), and for exploring the recurrence of duodenal ulcers. These studies were largely short-term RCTs, where the outcomes examined focused on the endoscopic healing rate of the ulcers and patient-reported symptom changes. Studies monitored and reported patterns observed in the measured healing rates.

For examining the return of duodenal ulcers (maintenance therapy), the rate of ulcer relapse was monitored in the observed populations during the maintenance phase over periods of 6 to 12 months.


Evidence for Managing Gastroesophageal Reflux Disease (GERD) and Heartburn

Research explored studies focused on symptom patterns associated with Gastroesophageal Reflux Disease (GERD) and occasional, episodic heartburn. For GERD, studies measured patient-reported symptom changes and the endoscopic healing rate of the esophageal lining. For over-the-counter use in episodic heartburn, studies explored outcomes related to acute changes, measuring the time it took for patients to report symptom changes and whether the administration was associated with a reduction in symptoms associated with meals.


Long-Term Research and Research Gaps

According to the evidence record, the most comprehensive long-term data available relates to maintenance therapy for duodenal ulcers, where studies observed patients for up to one year. However, for most other uses, the follow-up durations were limited in the published RCTs, and information for long-term outcomes is not well characterized for continuous use across the broad patient population.

Researchers note that the results from the available studies generally apply only to the populations studied and may not reflect the experience of individuals with complex comorbidities, as these groups are often excluded from major clinical trials. Studies involving pediatric patients (children and infants ge3 months) with GERD often had modest sample sizes, and long-term outcomes in young children are not fully established.

Key Studies & References

  1. Famotidine - StatPearls (FDA-Approved Indications, Dosing, Pharmacokinetics)
  2. Label: FAMOTIDINE tablet, film coated - DailyMed (Official US Prescribing Information)
  3. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Frequently Asked Questions (FAQ)

Common questions about Famot (FAQ)


Q: What is the main difference between Famot and similar over-the-counter medicines?

A: Famot (Famotidine) is officially classified as a Histamine-2 ( H2) receptor antagonist. This means it works by targeting a specific receptor in the stomach to reduce acid production. Other similar medicines, such as antacids, work by simply neutralizing the existing acid. Official product information indicates against using Famotidine with other acid reducers unless specifically directed by a health professional.

Q: How long does it take for Famot to start reducing symptoms?

A: Clinical pharmacology studies indicate that the acid-reducing action may begin approximately within one hour after oral administration. The duration of this acid inhibition for a typical dose is generally observed to last for about 10 to 12 hours.

Q: What is the longest someone can safely use Famot?

A: Regulatory guidance defines the maximum duration based on the condition being addressed. For the treatment of active ulcers, official guidelines describe a treatment duration, often up to eight weeks. For over-the-counter use in managing heartburn, official instructions specify that the product should not be taken for more than 14 days without consulting a health professional.

Q: Are there any food or drinks I must avoid while using Famot?

A: Official product information notes that Famotidine tablets may be taken with or without food. However, patient-focused labeling commonly lists certain items, such as alcohol, caffeine, chocolate, and rich, spicy, fatty, or fried foods, as potential heartburn-causing foods and beverages to consider reducing as part of symptom management.

Q: Can Famot be used by older adults (over 65)?

A: Famotidine is approved for use in adults, including the elderly population. Regulatory documents include warnings for the elderly population regarding a potentially higher occurrence of Central Nervous System ( CNS) adverse effects, such as confusion or delirium. Due to possible changes in kidney function with age, dose adjustments may be specified.

Q: When should I stop using Famot and talk to a health professional?

A: Official over-the-counter labeling indicates that consultation with a health professional is specified if heartburn continues or worsens. Consultation is also indicated if the medicine is needed for more than 14 days.

Q: Can Famot affect my ability to drive or operate machinery?

A: Official information on adverse reactions notes that Famotidine may cause certain effects such as dizziness or somnolence (drowsiness). These effects could potentially impact a person’s ability to drive or safely operate machinery, and caution is generally noted in official documents.

Q: What is Famot made of (active and inactive ingredients)?

A: The active substance in the medicine is Famotidine. The regulatory label for the specific product formulation also details a list of inactive ingredients. These are components that do not have a therapeutic effect but are necessary to create the tablet or liquid form.

Q: Is it possible to have a reaction to the inactive ingredients in Famot?

A: The primary allergy warning on the product label is for the active ingredient (Famotidine) or other acid reducers in the same class. The safety information primarily highlights the risk of serious hypersensitivity to the active ingredient.

Q: Do I need to change my diet while taking Famot?

A: Official product information emphasizes that the tablets can be taken with or without food. However, patient labeling generally mentions heartburn-causing foods (such as spicy, high-fat foods, or beverages like alcohol and caffeine) as items to manage in relation to the underlying symptoms.

Q: What are the long-term effects of taking Famot?

A: Clinical studies have examined the use of the drug for up to one year in the context of duodenal ulcer maintenance therapy. Safety and efficacy data are not officially established for continuous use beyond that duration for all indications, and research gaps exist for very long-term outcomes.

Q: Does Famot have an effect on sleep?

A: Certain side effects, such as somnolence (drowsiness) or psychic disturbances, have been reported in official documents, which could potentially interfere with sleep. For specific conditions, the prescription dosing regimens often include taking the medicine once daily at bedtime.

Q: Can Famot be used for acid reflux that happens at night?

A: Yes, official dosage guidelines support its use for night-time acid issues. For the treatment of active ulcers and similar conditions, one of the standard prescription dosing regimens involves administration once daily at bedtime.

Q: Do studies show Famot has been looked at for conditions other than its main use?

A: Regulatory-published reviews and clinical literature indicate that Famotidine has been investigated for off-label uses. These include, but are not limited to, treating refractory urticaria (hives) and potentially helping to prevent some of the gastrointestinal risks associated with certain pain relievers.

Q: How do scientists know that Famot gets absorbed correctly?

A: Clinical pharmacology studies demonstrate that the drug is incompletely absorbed after oral administration, with about 40% to 45% of the dose reaching the bloodstream. The studies also show that the peak blood concentration is typically reached within 1 to 3 hours after taking the tablet.

Q: Why is the drug Famot available in different strengths?

A: Official labeling lists various strengths (e.g., 10 mg, 20 mg, 40 mg) to accommodate different dosing regimens for various conditions. For instance, lower strengths are intended for occasional heartburn, while higher strengths may be needed for managing active ulcers or severe acid-producing conditions.

Q: Can Famot be crushed or chewed?

A: The product directions for standard film-coated tablets typically specify to swallow the tablet whole with water and to not chew the tablet. There are, however, specialized formulations that are specifically designed to be chewable.

Q: Is it safe to drink alcohol while using Famot?

A: Official patient labeling advises avoiding alcohol as a potential heartburn-causing beverage. Official labeling focuses on the fact that alcohol is listed as a potential heartburn-causing beverage.

Q: Why do some forums discuss a link between Famot and Vitamin B12 levels?

A: Clinical information accompanying the drug notes that long-term acid-reducing effects may cause a decrease in Vitamin B12 levels. Official guidance indicates that consultation with a health professional is generally appropriate to discuss Vitamin B12 status while taking this medication.

Q: How is the safety of Famot monitored after it is approved?

A: After the drug is approved and available to the public, its safety is continuously monitored through a process called postmarketing surveillance. This involves collecting and analyzing reports of any adverse events experienced by individuals using the product.

Q: Are there any lifestyle changes that improve how well Famot works?

A: Official patient information often includes lifestyle tips for managing heartburn symptoms, which may be used alongside the medication. These often include avoiding certain foods, avoiding lying flat immediately after eating, and raising the head of the bed during sleep.

How should Famot be stored and disposed of?

How to Store and Dispose of Famot?

Famot (famotidine) must be stored according to official regulatory guidelines to maintain stability and effectiveness.

Storage Requirements

The product must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) and kept from freezing. Storage must occur in a well-closed, light-resistant container, and the product must be protected from moisture and direct light. The medicine must always be stored out of the reach of children.

Stability and Disposal

The oral liquid formulation must be discarded after 30 days of reconstitution or opening. Do not flush unused or expired medication down the toilet. Dispose of Famot by taking it to a drug take-back program or by following the official guideline of mixing it with an unappealing substance, sealing it in a bag, and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Famot found in:

A-Z Index: